Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
Israel got an early start on vaccinating its population and began offering a third dose of mRNA vaccine in July to the older age group (≥ 60 years). The results from an observational study comparing the clinical outcome of participants who received a third shot to those in the same age group who had received only two shots over the same period clearly indicated that the risk of severe disease dropped by a factor of almost 20. Additionally, those who received the third dose were also enjoying some level of protection against infection as they were also less likely to test positive for SARS-CoV-2 (1).
These are strong results, and at first glance, many of those within this age group and not yet boosted might feel ashamed for their indifference in protecting themselves and others! However, there is a catch, and it’s not about potential biases in the analysis of the study results or criticism from a public health perspective of delivering additional shots to individuals while many others have not even had their first.
The caveat is much m...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).